- Additional Authors
- Description
- 1 online resource (iii, 37 pages) : illustrations (chiefly color)
- Summary
- There is great potential to improve health outcomes for Veterans and other patients with chronic genotype 1 (GT1) Hepatitis C (HCV) infections through the use of newly-available triple combination therapies that include directly acting antivirals (DAA) along with recently developed patient genotyping (IL-28B) which is predictive of HCV treatment response. Chronic GT1 HCV infections have been historically difficult to treat, with low cure rates on standard two drug therapy (Pegylated Interferon + Ribavirin), high rates of side-effects and treatment discontinuation, and low rates of uptake. Recently, FDA approved two DAAs (boceprevir and telaprevir). Used in combination with standard two drug therapy as triple therapy, these DAAs show higher rates of sustained viral response, though they are also more costly and have more severe side-effect profiles. IL-28B genotyping can help to identify patients least likely to respond to standard therapy and hence who stand to benefit the most from triple therapy and for whom, therefore, the increased risks of side-effects may be most justified.
- Subject
- Genre/Form
- Technical reports.
- Note
- "Evidence-based synthesis program."
- "March 2013."
- Bibliography (note)
- Includes bibliographical references (pages 29-31).
- Funding (note)
- Prepared for: Department of Veterans Affairs, Veterans Health Administration, Quality Enhancement Research Initiative, Health Services Research & Development Service, Washington, DC 20420. Prepared by: Evidence-based Synthesis Program (ESP) Center, West Los Angeles VA Medical Center, Los Angeles, CA, Paul G. Shekelle, MD, PhD, Director. VA Health Economics Resource Center, Menlo Park, CA, Paul G. Barnett, PhD, Director
- VA ESP
- Source of Description (note)
- Description based on online resource; title from PDF cover (VA, viewed April 16, 2021).
- Call Number
- GPO Internet VA 1.107/3:H 41/2
- OCLC
- marcive862321793
- Author
Goldhaber-Fiebert, Jeremy D., author.
- Title
Assessment of alternative treatment strategies for chronic genotype 1 hepatitis C / Jeremy D. Goldhaber-Fiebert [and nine others].
- Publisher
Washington, DC : Department of Veterans Affairs, Veterans Health Administration, Quality Enhancement Research Initiative, Health Services Research & Development Service, 2013.
- Type of Content
text
- Type of Medium
computer
- Type of Carrier
online resource
- Bibliography
Includes bibliographical references (pages 29-31).
- Funding
Prepared for: Department of Veterans Affairs, Veterans Health Administration, Quality Enhancement Research Initiative, Health Services Research & Development Service, Washington, DC 20420. Prepared by: Evidence-based Synthesis Program (ESP) Center, West Los Angeles VA Medical Center, Los Angeles, CA, Paul G. Shekelle, MD, PhD, Director. VA Health Economics Resource Center, Menlo Park, CA, Paul G. Barnett, PhD, Director
VA ESP 05-226
- Connect to:
- Added Author
United States. Department of Veterans Affairs. Health Services Research and Development Service, issuing body.
West Los Angeles VA Medical Center. Evidence-Based Synthesis Program Center.
VA Health Economics Resource Center (U.S.)
Quality Enhancement Research Initiative (U.S.)
Evidence-based Synthesis Program (U.S.)
- Gpo Item No.
0985-A-12 (online)
- Sudoc No.
VA 1.107/3:H 41/2